Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Overcoming Psychomotor Slowing in Psychosis (OCoPS-P) (OCoPS-P)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03921450
Recruitment Status : Recruiting
First Posted : April 19, 2019
Last Update Posted : April 29, 2020
Sponsor:
Information provided by (Responsible Party):
University of Bern

Brief Summary:
Psychomotor slowing is a major problem in psychosis. Aberrant function of the cerebral motor system is linked to psychomotor slowing in patients, particularly resting state hyperactivity in premotor cortices. A previous clinical trial indicated that inhibitory stimulation of the premotor cortex would reduce psychomotor slowing. The current study is further exploring this effect in a randomized, placebo-controlled, double-blind design with three arms of transcranial magnetic stimulation and measures of brain imaging and physiology prior to and after the intervention.

Condition or disease Intervention/treatment Phase
Schizophrenia and Related Disorders Schizophrenia Schizoaffective Disorder Brief Psychotic Disorder Device: 1 Hz rTMS Device: iTBS Drug: Placebo Not Applicable

Detailed Description:

As psychomotor slowing is a major problem in schizophrenia, contributing to poor functional outcome, and as no current treatment is effectively targeting psychomotor slowing, this study seeks to test noninvasive brain stimulation to overcome psychomotor slowing. Previous studies documented an aberrant increase of neural activity within the supplementary motor area (SMA) in patients with schizophrenia who had psychomotor slowing. Furthermore, a pilot study in major depression and schizophrenia indicated that inhibitory 1 Hz repetitive transcranial magnetic stimulation (rTMS) would improve psychomotor slowing in 82% of the participants. While this is encouraging, further evidence is needed to 1) replicate the clinical effect of 1 Hz rTMS on the SMA in schizophrenia, 2) to test against sham stimulation, facilitatory stimulation and no intervention, and 3) to test the effects of rTMS on the neural circuitry. Therefore, OCoPS includes more patients, more treatment arms, and more outcome variables than the first pilot trial.

Here we will enroll 88 patients with schizophrenia spectrum disorders and severe psychomotor slowing according to a standard rating scale. Subjects will be randomized to four arms, three of which are double blinded.

three weeks of daily rTMS over the SMA will be delivered. The first group receives inhibitory 1 Hz rTMS, the second group receives facilitatory intermittent theta burst stimulation (iTBS), and the third group receives sham stimulation with a placebo-coil. The fourth group will have no rTMS during the first three weeks, but will repeat the baseline measures after three weeks and then enter a treatment with 1Hz rTMS for three weeks. Outcome measures include the Salpetriere Retardation Rating Scale, observer ratings of motor behavior as well as measures of functioning. After the interventions, follow-up visits are planned at week 6 and week 24.

Finally, at baseline and after the rTMS course, patients will undergo MRI scanning for structural and functional alterations of the cerebral motor system.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 3 week intervention with 15 sessions of add-on rTMS in 4 parallel arms, randomized, double-blind, placebo-controlled
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description: Participants will not know the stimulation protocol, neither will the outcome assessor or the mental health care provider know the protocol applied
Primary Purpose: Treatment
Official Title: Overcoming Psychomotor Slowing in Psychosis (OCoPS-P): a 3-week, Randomized, Double-blind, Placebo-controlled Trial of add-on Repetitive Transcranial Magnetic Stimulation for Psychomotor Slowing in Psychosis
Actual Study Start Date : March 25, 2019
Estimated Primary Completion Date : February 1, 2023
Estimated Study Completion Date : January 1, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Inhibitory repetitive transcranial magnetic stimulation (rTMS)
1 Hz stimulation of 17 mins over the supplementary motor area (SMA), 1000 pulses at 110% resting motor threshold intensity total of 15 sessions in 3 weeks
Device: 1 Hz rTMS
1 Hz stimulation at 110% of resting motor threshold over supplementary motor area

Active Comparator: Facilitatory intermittent theta burst stimulation (iTBS)

Intermittent theta burst stimulation of 50 Hz over the supplementary motor area (SMA) with 600 pulses in 2 sec trains every 10 seconds for 190 seconds total. Two iTBS stimulations will be administered with 15 mins pause in between.

total of 15 sessions in 3 weeks

Device: iTBS
50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area

Placebo Comparator: Placebo
1 Hz stimulation of 17 mins over the supplementary motor area (SMA) without any magnetic emission using a placebo-coil that looks identical and makes identical sounds as the real TMS coil total of 15 sessions in 3 weeks
Drug: Placebo
1 Hz stimulation with the placebo TMS coil without any magnetic emission

No Intervention: Waiting group
This group will receive no intervention for 3 weeks. Afterwards they will receive the inhibitory rTMS protocol as in the first arm



Primary Outcome Measures :
  1. Proportion of responders at week 3 [ Time Frame: Week 3 ]
    Proportion of participants with >30% reduction from baseline in the Salpetriere Retardation Rating Scale (SRRS)

  2. Change in Salpetriere Retardation Rating Scale (SSRS) from baseline [ Time Frame: Week 3, week 6, week 24 ]
    Change in the Salpetriere Retardation Rating Scale (SRRS) from baseline; the total score of 15 items is used, ranging 0-60 with higher scores indicating worse outcome


Secondary Outcome Measures :
  1. Change in catatonia severity from baseline to week 3 [ Time Frame: Week 3, week 6, week 24 ]
    Observer based rating of catatonia severity with the Bush Francis Catatonia Rating Scale (BFCRS), assessment blind to intervention, total score of the BFCRS is used ranging 0-69 , with higher scores indicating poorer outcome

  2. Change in negative symptoms from baseline [ Time Frame: Week 3, week 6, week 24 ]
    Change in the Brief Negative Symptom Scale (BNSS) from baseline, total score is used, ranging from 0-78 with higher values indicating poorer outcome, i.e. more negative symptom severity

  3. Change in psychosis severity from baseline [ Time Frame: Week 3, week 6, week 24 ]
    Change in the Positive And Negative Symptom Scale (PANSS) from baseline, PANSS total score assesses the severity of positive, negative and general symptoms, ranging from 30-210 with higher scores indicating increased symptom severity, i.e. poorer outcome

  4. Change in physical activity self report from baseline [ Time Frame: Week 3, week 6, week 24 ]
    Change in the International Physical Activity Questionnaire (IPAQ), the total score is used ranging from 0-70000 metabolic equivalent (MET)

  5. Change in objectively measured physical activity from baseline [ Time Frame: Week 3, week 6, week 24 ]
    Change in the activity levels using wrist actigraphy

  6. Change in dexterity from baseline [ Time Frame: Week 3, week 6, week 24 ]
    Change in the coin rotation task from baseline

  7. Change in cortical excitability of the motor cortex from baseline [ Time Frame: Week 3, week 6, week 24 ]
    Change in Short Interval Cortical Inhibition (SICI) from baseline

  8. Change in social and community functioning [ Time Frame: Week 3, week 6, week 24 ]
    Change in Social and Occupational Functional Assesment Scale (SOFAS) from baseline, the score ranges from 0-100 with higher scores indicating better functioning, i.e. better outcome

  9. Change in functional capacity [ Time Frame: Week 3, week 6, week 24 ]
    Change in the Score of the brief version of the University of California, San Diego, Performance-Based Skills Assessment (UPSA-brief) assessment from baseline, higher scores indicating better function, the total score is used ranging 0-100

  10. Change in functional connectivity [ Time Frame: Week 3 ]
    Change in the resting state functional connectivity within the cerebral motor system based on functional magnetic resonance imaging scans from baseline

  11. Change in resting state cerebral perfusion [ Time Frame: Week 3 ]
    Change in the resting state cerebral perfusion within the cerebral motor system based on functional magnetic resonance imaging scans from baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Right-handed subjects
  • Ability and willingness to participate in the study
  • Ability to provide written informed consent
  • Informed Consent as documented by signature
  • Schizophrenia spectrum disorder according to diagnostic and statistical manual version 5 (DSM-5) criteria with current psychomotor slowing according to the Salpetriere Retardation Rating Scale (SRRS), score >= 15

Exclusion Criteria:

  • Substance abuse or dependence other than nicotine
  • Past or current medical or neurological condition associated with impaired or aberrant movement, such as brain tumors, stroke, M. Parkinson, M. Huntington, dystonia, or severe head trauma with subsequent loss of consciousness.
  • Epilepsy or other convulsions
  • History of any hearing problems or ringing in the ears
  • Standard exclusion criteria for MRI scanning and TMS; e.g. metal implants, claustrophobia
  • Patients only: any TMS treatment in the past 3 months
  • Women who are pregnant or breast feeding,
  • Intention to become pregnant during the course of the study,
  • Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Controls only: history of any psychiatric disorder or first-degree relatives with schizophrenia spectrum disorders.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03921450


Contacts
Layout table for location contacts
Contact: Sebastian Walther, MD +41316328979 sebastian.walther@upd.unibe.ch
Contact: Stéphanie Lefebvre, PhD stephanie.lefebvre@upd.unibe.ch

Locations
Layout table for location information
Switzerland
University Hospital of Psychiatry Recruiting
Bern, Switzerland, 3000
Contact: Niluja Nadesalingam, MSc       niluja.nadesalingam@upd.unibe.ch   
Sub-Investigator: Danai Alexaki, MD         
Principal Investigator: Sebastian Walther, MD         
Sponsors and Collaborators
University of Bern
Investigators
Layout table for investigator information
Principal Investigator: Sebastian Walther, MD University of Bern
  Study Documents (Full-Text)

Documents provided by University of Bern:
Layout table for additonal information
Responsible Party: University of Bern
ClinicalTrials.gov Identifier: NCT03921450    
Other Study ID Numbers: 2018-02164
First Posted: April 19, 2019    Key Record Dates
Last Update Posted: April 29, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Bern:
motor behavior
psychomotor slowing
psychosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Schizophrenia
Psychotic Disorders
Mental Disorders
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders